Drug Approval | June 19, 2023
Lupin launches Thiamine Hydrochloride Injection USP in the US
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Thiamine Hydrochloride Injection USP had estimated annual sales of USD 35 million in the U.S.
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Urges Innovators to produce quality products that can be deployed at scale
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Pfizer is likely to show GSK significant competition
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
Subscribe To Our Newsletter & Stay Updated
